Q2 FY2026 · ended Jun 30, 2026 · Revenue $7.90M · Filed Aug 12, 2026
BioStem Technologies, Inc. (BSEM) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $7.9 million and a net loss of $9.0 million. Free cash flow was -$6.4 million. As of Jun 30, 2026 it held $7.0 million in cash and investments and $223,826 in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BSEM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Pompano Beach, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1658678
- Former names
- BIOSTEM TECHNOLOGIES (until Oct 28, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Revenue | $7.9M |
| Operating income | -$8.4M |
| Net income | -$9.0M |
| Diluted EPS | -$0.52 |
| Operating cash flow | -$6.4M |
| Free cash flow | -$6.4M |
| Total assets | $48.8M |
| Total liabilities | $21.2M |
| Stockholders' equity | $27.6M |
| Cash and investments | $7.0M |
| Total debt | $223,826 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 7, 2026 | Aug 6, 2026 |
All 75 BioStem Technologies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.